Why the study?
The impact of concurrent adherence to antihypertensives, antidiabetics, and statins on cardiovascular disease outcomes and intermediate clinical outcomes in people with hypertension and diabetes remains unclear.
Does high medication adherence reduce cardiac events and all-cause mortality in adults with both diabetes and hypertension?
Does high medication adherence reduce cardiac events and all-cause mortality in adults with both diabetes and hypertension?
High adherence to antidiabetic and statin therapies is associated with reduced all-cause mortality and improved intermediate clinical outcomes in patients with concurrent diabetes and hypertension.
Answers are grounded in this paper and cite their sources.
Supports adherence counseling in diabetes-hypertension; hypothesis-generating and should not yet change practice without RCTs.
OBJECTIVES: The impact of concurrent adherence to antihypertensives, antidiabetics, and statins on cardiovascular disease (CVD) outcomes and intermediate clinical outcomes in people with hypertension and diabetes remains unclear. This study aimed to evaluate the association between medication adherence and CVD outcomes in such patients. METHODS: This retrospective cohort study analyzed the electronic medical records of 36,211 adults aged 18 or older diagnosed with hypertension and diabetes between January 2008 and June 2016 in Canada. Patients were prescribed antihypertensives, antidiabetics, and statins, with a minimum 1-year follow-up post-diagnosis. Medication adherence was determined by the proportion of days covered (PDC). For monotherapy, a PDC≥80% and <80% was reflected high and low adherence respectively. In multiple medication scenarios, adherence was considered high when each medication was at PDC≥80%; low when any medication fell below 80%. The primary outcome encompassed cardiac events, including coronary heart disease, stroke, and heart failure. Intermediate clinical outcomes included changes in diastolic blood pressure (DBP), Systolic Blood Pressure (SBP), glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and total cholesterol (TC). Cox regression models assessed the association between medication adherence and CVD morbidity, all-cause mortality, and intermediate clinical outcomes. RESULTS: High adherence to antidiabetic and statin monotherapy was associated with a lower all-cause mortality risk (aHR=0.67, P=0.001; aHR=0.68, P<0.001, respectively). For patients simultaneously prescribed three medications, higher adherence was linked to significant reductions in DBP (6 months: coefficient -0.52, P=0.01; 12 months: coefficient -0.44, P=0.02; 18 months: coefficient -0.55, P=0.004) and LDL-C (6 months: coefficient -0.04, P=0.02; 12 months: coefficient -0.05, P=0.01; 18 months: coefficient -0.04, P=0.02). CONCLUSIONS: High adherence to antidiabetic and statin monotherapy correlated with lower all-cause mortality risk and improved intermediate clinical outcomes. However, simultaneous adherence to three medications did not significantly affect CVD outcomes, but influenced intermediate outcomes. Therefore, improving adherence to antihypertensives, antidiabetics, and statins among patients with hypertension and diabetes is important in primary care settings.
No takes yet. Share an insight, caveat, or question.
Su et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: